Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-M 200 vs ISOVUE-128
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar),CT cisternography,Ventriculography
Intravascular use for computed tomography (CT) imaging,Intravenous urography,Intra-arterial angiography (including coronary, peripheral, and cerebral),Ventriculography,Myelography (subarachnoid injection for spinal imaging),Off-label: Arthrography, hysterosalpingography (though not FDA-approved for these)
Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.
Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 m L/min).
Not metabolized; excreted unchanged by the kidneys. Undergoes passive resorption from cerebrospinal fluid into plasma.
Iopamidol is not metabolized and is excreted unchanged almost entirely by the kidneys via glomerular filtration. No hepatic metabolism or significant protein binding occurs.
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Negligible, <2% bound to plasma proteins.
Minimal protein binding (<5%), primarily to albumin.
Approximately 0.3–0.4 L/kg, consistent with distribution into extracellular fluid space.
Approximately 0.2-0.3 L/kg, reflecting distribution into extracellular fluid.
Not applicable; administered intravenously or intra-arterially, with 100% bioavailability by these routes.
Not applicable for oral route (no oral formulation); 100% bioavailability via intravenous or intra-arterial administration.
e GFR ≥30 m L/min: No adjustment. e GFR <30 m L/min: Contraindicated due to risk of nephrogenic systemic fibrosis (NSF) with gadolinium-based agents; however, for iopamidol-based Isovue-M 200, renal impairment requires dose reduction and careful monitoring. In severe renal impairment (e GFR <30 m L/min), use lowest effective dose and ensure adequate hydration; consider alternative imaging.
GFR <30 m L/min: use lowest feasible dose; GFR <15 m L/min: avoid use unless essential; consider hydration and N-acetylcysteine.
No specific Child-Pugh based adjustments recommended; use with caution in severe hepatic impairment due to potential for contrast-induced nephropathy and systemic effects.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of contrast-induced nephropathy.
Intrathecal: 0.2-0.4 m L/kg (up to 12 m L total) for myelography. Intravenous: 1.5-2.5 m L/kg (max 200 m L) for CT or angiography, adjusted per procedure.
Neonates: 0.5-1 m L/kg IV; Infants/Children: 1-2 m L/kg IV (max 125 m L per dose) for contrast-enhanced CT.
Use with caution due to increased prevalence of renal impairment, cardiovascular disease, and dehydration. Assess renal function before use; ensure adequate hydration; consider lower doses and longer intervals between procedures.
Reduce dose to lowest effective (e.g., 50-100 m L); ensure adequate hydration; monitor renal function pre and post administration.
Risk of serious adverse reactions including anaphylaxis, seizures, and neurological complications when administered intrathecally. Use only by physicians trained in myelography and familiar with the procedure. Resuscitative equipment and trained personnel must be immediately available.
Iodinated contrast media including iopamidol are associated with an increased risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing renal impairment, particularly those with diabetes, volume depletion, or concurrent use of nephrotoxic drugs. Strict adherence to hydration protocols and renal monitoring is required.
Risk of anaphylactoid reactions, especially in patients with history of allergy or bronchial asthma,Seizures may occur, particularly in patients with epilepsy or when concurrent medications lower seizure threshold,Renal impairment delays elimination and increases risk of adverse effects,Adequate hydration before and after procedure is essential,Neurotoxicity: avoid hemorrhage or infection at puncture site, do not use in patients with increased intracranial pressure
Risk of contrast-induced nephropathy (CIN): Monitor renal function before and after administration, ensure adequate hydration, and avoid concurrent nephrotoxic agents.,Severe hypersensitivity reactions (e.g., anaphylaxis, bronchospasm): Have resuscitation equipment available; premedication may be considered for patients with known contrast allergy.,Thyroid dysfunction: Iodinated contrast may induce hyperthyroidism or hypothyroidism; caution in patients with thyroid disease.,Cardiovascular events: In patients with heart failure, coronary artery disease, or pulmonary hypertension, contrast media can cause hemodynamic instability, arrhythmias, or myocardial ischemia.,Neurologic effects: Intrathecal administration may cause seizures, arachnoiditis, or aseptic meningitis; use lowest possible dose and monitor for neurotoxicity.,Extravasation: Risk of tissue necrosis; administer through a secure IV line and monitor injection site.
Known hypersensitivity to iopamidol or any component of the formulation,Concurrent intrathecal administration of corticosteroids or other contrast agents,Blood in CSF (hemorrhagic puncture) due to increased risk of neurotoxicity,History of seizures or epilepsy (relative contraindication depending on benefit-risk),Severe renal impairment (relative, may be used after dialysis if necessary)
Absolute: Known hypersensitivity to iopamidol, other iodine-containing contrast media, or any component of the formulation.,Absolute: Intrathecal administration in patients with significant thrombophlebitis or infection at the injection site.,Relative: Pre-existing renal impairment (e GFR <30 m L/min/1.73m²) unless benefits outweigh risks; consider alternative imaging.,Relative: Multiple myeloma, pheochromocytoma, sickle cell disease (due to risk of vaso-occlusive events).,Relative: Pregnancy (especially first trimester) unless essential for diagnosis.
No specific food interactions. Maintain adequate hydration before and after contrast administration. Avoid alcohol consumption for 24 hours post-procedure as it may exacerbate CNS side effects.
No specific food interactions. However, patients are often advised to maintain adequate hydration. Avoid alcohol consumption for 24 hours before and after the procedure as it may increase risk of dehydration. No dietary restrictions required.
Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when administered to a pregnant woman. However, iodinated contrast agents cross the placenta and accumulate in the fetal thyroid, potentially causing hypothyroidism. Use during pregnancy should be limited to situations where the diagnostic benefit clearly outweighs the risk. First trimester exposure is not advised due to organogenesis. Second and third trimester use may be considered with caution, but neonatal thyroid function should be assessed after birth.
Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is a theoretical risk of fetal hypothyroidism due to free iodide, but clinical evidence does not show a significant increase in congenital anomalies. Second and third trimester exposure is associated with transient neonatal hypothyroidism if the agent crosses the placenta, but no structural teratogenic effects are documented. The FDA assigns a Pregnancy Category B for iodinated contrast agents.
Iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma ratio (M/P) is approximately 0.01. After IV administration, the amount ingested by a nursing infant is minimal (<0.1% of the maternal dose). Because of the low bioavailability of oral iodinated contrast agents, adverse effects in the infant are unlikely. The American College of Radiology considers it safe to continue breastfeeding after use of iodinated contrast agents. However, some guidelines suggest discarding breast milk for 12-24 hours after administration if desired.
Iopamidol is excreted into breast milk in very small amounts. The milk-to-plasma (M/P) ratio is approximately 0.04–0.08 based on limited studies. The absolute dose received by a nursing infant is estimated to be less than 0.01% of the maternal dose, which is clinically insignificant. Therefore, breastfeeding can be continued without interruption, although some experts suggest discarding milk for 24 hours post-administration as a precaution. No adverse effects on the infant have been reported.
No specific dose adjustment is required for iopamidol (ISOVUE-M 200) during pregnancy. However, the lowest effective dose necessary for diagnostic imaging should be used. The physiological changes of pregnancy (increased plasma volume, renal blood flow and GFR) may alter the pharmacokinetics of iopamidol, potentially leading to faster clearance. Nonetheless, no dose adjustment is recommended as contrast dosing is weight-based and the agent is used as a single dose for imaging.
No dosing adjustments are required for iopamidol (ISOVUE-128) during pregnancy based on pharmacokinetic changes. However, because physiological changes in pregnancy (increased plasma volume, increased renal clearance) may affect contrast agent distribution and elimination, the standard dose should be used based on body weight and indication. The lowest effective dose should be administered to minimize fetal exposure. No specific dose modifications are recommended in guidelines.
ISOVUE-M 200 (iopamidol) is a nonionic, low-osmolar iodinated contrast medium used for intrathecal administration in myelography. Pre-hydrate patients to reduce risk of contrast-induced nephropathy. Have resuscitation equipment available due to risk of anaphylactoid reactions. Avoid in patients with known hypersensitivity to iodine-containing compounds. Monitor for delayed adverse effects such as headache, nausea, and meningeal irritation.
ISOVUE-128 (iopamidol) is a nonionic, low-osmolality contrast medium. Pre-warming to body temperature reduces viscosity and improves patient tolerance. Risk of contrast-induced nephropathy (CIN) increases with pre-existing renal impairment; assess renal function (e GFR) prior to administration. Adequate hydration is critical. Monitor for delayed hypersensitivity reactions (up to 7 days). Metformin should be withheld for 48 hours post procedure if renal function is compromised. Have emergency equipment available for anaphylactoid reactions.
Inform your healthcare provider if you have any allergies, especially to iodine or contrast agents.,Tell your doctor if you have kidney problems, diabetes, or are taking certain medications like metformin.,Drink plenty of fluids before and after the procedure to help flush the contrast from your body.,You may experience headache, nausea, or back pain after the injection; report severe or persistent symptoms.,Avoid driving or operating machinery for at least 24 hours after the procedure due to possible dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or suspect you may be pregnant.
Inform your healthcare provider if you have any allergies, especially to contrast media or iodine.,Tell your provider about all medications you take, particularly metformin or any kidney-affecting drugs.,You may be asked to drink extra fluids before and after the procedure to protect your kidneys.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you have diabetes and take metformin, your doctor may advise stopping it for 48 hours after the scan.,Sensation of warmth, a metallic taste, or nausea during injection is common and usually resolves quickly.,After the procedure, you can resume normal diet unless directed otherwise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-M 200 vs ISOVUE-128, answered by our medical review team.
ISOVUE-M 200 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.. ISOVUE-128 is a Contrast Media that works by Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-M 200 and ISOVUE-128 depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-M 200 is: Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.. The standard adult dose of ISOVUE-128 is: Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-M 200 and ISOVUE-128 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-M 200 is classified as Category C. Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when ad. ISOVUE-128 is classified as Category C. Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.